Lonza to make Bluebird Bio drugs | Chemical & Engineering News
Volume 94 Issue 25 | p. 13 | Concentrates
Issue Date: June 20, 2016

Lonza to make Bluebird Bio drugs

Department: Business
Keywords: biologics, contract manufacturing, gene therapy, viral vectors

Lonza has agreed to manufacture future commercial supplies of two lentiviral-based gene therapies for Bluebird Bio, a developer of drugs for genetic diseases and T cell-based immunotherapies for cancer. The two companies already have a multiyear relationship for clinical-scale materials. Now Lonza will build a dedicated production suite at its facility near Houston. The 9,300 m2 site, set to be completed in 2017, is designed to produce viral vectors and virally-modified cell therapy products using single-use bioreactors.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment